GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Short Interest

Oxurion NV (XBRU:OXUR) Short Interest


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Oxurion NV's Short Interest

For the Biotechnology subindustry, Oxurion NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Short Interest distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Short Interest falls into.


Oxurion NV (XBRU:OXUR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Short Interest
Comparable Companies
XBRU:BIOS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB ALNY BGNE BMRN RPRX SRPT SHSE:603392 SZSE:300122 INCY
Traded in Other Exchanges
TG4:Germany
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Website
https://www.oxurion.com
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines